Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
You may also be interested in...
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
Novartis is under pressure to deliver new drugs in areas like oncology, cardiovascular disease and dermatology, where it is making significant investments. Chief Medical Officer Vasant Narasimhan talked about the company’s strategy in these areas and others, the company’s recent R&D reorganization and business development in an interview during the J.P. Morgan Healthcare Conference.
AstraZeneca has entered a broad early stage collaboration with Bicycle Therapeutics to discover and develop bicyclic peptides (Bicycles). If all aspects of the multitarget deal reach fruition, the deal could be worth up to £1bn for the small biotech company.